Search for Clinical Trial Results

Cutaneous T-cell Lymphoma - 27 Studies Found
Status | Study |
Completed |
Study Name: Open-label Pilot Study of Lenalidomide (Revlimid) as Adjuvant Treatment for Refractory Cutaneous T Cell Lymphoma Condition: Cutaneous T Cell Lymphoma Date: 2010-05-25 Interventions: Drug: Lenalidomide Lenalidomide Starting Dose Based on Renal Function at Study Entry Baseline Calculated |
Recruiting |
Study Name: Micro Needle Array-Doxorubicin (MNA-D) in Patients With Cutaneous T-cell Lymphoma (CTCL) Condition: Cutaneous T Cell Lymphoma Date: 2014-07-10 Interventions: Drug: Micro needle array-Doxorubicin (MNA-D) MNA-D patches will be applied to 3-4 CTCL skin patches or p |
Completed |
Study Name: Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma Condition: Cutaneous T-Cell Lymphoma Date: 2007-01-22 Interventions: Drug: Panobinostat Other Name: LBH589 |
Terminated |
Study Name: Recalcitrant Pruritus in Cutaneous T-Cell Lymphoma Condition: Cutaneous T-Cell Lymphoma Date: 2009-02-24 Interventions: Procedure: skin biopsy Lidocaine 1% c Epinephrine for local anesthesia |
Withdrawn |
Study Name: Trial of Curcumin in Cutaneous T-cell Lymphoma Patients Condition: Cutaneous T-cell Lymphoma Date: 2009-08-27 Interventions:
|
Completed |
Study Name: A Study of APO866 for the Treatment of Cutaneous T-cell Lymphoma Condition: Cutaneous T-cell Lymphoma Date: 2007-02-05 Interventions: Drug: APO866 APO866 is administered as 0.126 mg/m²/hr for 4 consecutive days (96 hours), every 3 we |
Completed |
Study Name: Study of Oral LBH589 in Adult Patients With Refractory/Resistant Cutaneous T-Cell Lymphoma Condition: Cutaneous T-Cell Lymphoma Date: 2007-06-21 Interventions: Drug: LBH589 Other Name: panobinostat |
Completed |
Study Name: Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma Condition: Cutaneous T-cell Lymphoma Date: 2007-11-05 Interventions:
|
Terminated |
Study Name: Everolimus in Treating Cutaneous T-cell Lymphoma Condition: Cutaneous T-Cell Lymphoma Date: 2012-04-02 Interventions: Drug: Everolimus The study drug everolimus will be self-ad |
Recruiting |
Study Name: A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma Condition: Persistent or Recurrent Cutaneous T-Cell Lymphoma Date: 2013-03-28 Interventions: Drug: E7777 administered by intravenous (i.v.) infusion over 60 minutes (+/-10 minutes) on 5 consecutive |